Which Is First Argon Laser Therapy Or Intravitreal Bivacizumab In Branch Retinal Vein Occlusion With Macular Oedema.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201705002168252

Enrollment

Registered

2017-04-03

Start date

2016-09-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases Macular edema, branch retinal vein occlusion

Interventions

argon macular grid laser followed by intravitreal bivacizumab

intravitreal bivacizumab followed by argon macular grid laser

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with macular edema secondary to branch retinal vein occlusion

Exclusion criteria

Exclusion criteria: The patients who had coexisting retinal disease (like diabetic retinopathy and epiretinal membrane); media opacities that could decrease visual acuity, or macular ischemia, concurrent ocular in¿ammation or infection, intraocular surgery (including post vitrectomized eyes) within the previous 3 months, patients of incomplete follow up

Design outcomes

Primary

Measure	Time frame
Best corrected visual effect	—

Secondary

Measure	Time frame
central foveal thickness	—

Countries

Egypt

Contacts

Public ContactAhmad Moustafa

amoustafa77@hotmail.com00201023092323

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026